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Epidemiologyconsecutivepatients undergoing allo-HSCT between 2008 and 2010. Logistic regression analysiswas performed
to identify risk factors for proven/probable IFD (PP-IFD) during the early (days 0 to 40), late (days 41 to 100), and
very late (days 101 to 365) phases after allo-HSCT and to evaluate the impact of PP-IFDs on 1-year overall
survival. The cumulative incidence of PP-IFDswas 5.1% at 40 days, 6.7% at 100 days, and 8.8% at 12months post-
transplantation. Multivariate analysis identiﬁed the following variables as associated with PP-IFDs: transplant
from an unrelated volunteer donor or cord blood, active acute leukemia at the time of transplantation, and an
IFD before transplantation in the early phase; transplant from an unrelated volunteer donor or cord blood and
grade II-IV acute graft-versus-host disease (GVHD) in the late phase; and grade II-IV acute GVHD and extensive
chronic GVHD in the very late phase. The risk for PP-IFD was signiﬁcantly higher when acute GVHD was fol-
lowed by chronic GVHD and when acute GVHD occurred in patients undergoing transplantation with grafts
from other than matched related donors. The presence of PP-IFD was an independent factor in long-term
survival (hazard ratio, 2.90; 95% conﬁdence interval, 2.32 to 3.62; P < .0001). Our ﬁndings indicate that
tailored prevention strategies may be useful in subpopulations at differing levels of risk for PP-IFDs.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION status of underlying diseases, proven and probable IFDs (PP-IFDs), survival,
Invasive fungal diseases (IFDs), particularly invasive
aspergillosis (IA), represent a leading cause of morbidity and
mortality in recipients of allogeneic hematopoietic stem cell
transplantation (allo-HSCT) [1-14]. Ongoing challenges are
presented by the continuous evolution of the incidence,
timing, and prognosis of IFDs owing to changes in transplant
recipient populations and antifungal strategies. Therefore,
ongoing epidemiologic investigation is advisable.
Given thepooroutcomes associatedwith IFDs in transplant
recipients, there ismuch interest in identifying risk factors and
prognostic factors that may help guide the development of
tailored prevention strategies andmore aggressive diagnostic
and treatment approaches [2,3,8-10,12,14,15]. Although risk
factors for IFDs have been evaluated extensively in allo-HSCT
recipients, there are few studies describing speciﬁc variables
related to outcome [1,2,8,9].
To assess the current incidence, risk factors, and prog-
nostic factors of IFDs in allo-HSCT patients, the Gruppo
Italiano Trapianto Midollo Osseo (GITMO) prospectively
registered data of patients undergoing allo-HSCT between
2008 and 2010. These data provide the basis for promoting
direct efforts in risk stratiﬁcation, prevention, and manage-
ment of IFDs in allo-HSCT recipients.
METHODS
The surveillance involved 30 transplantation centers in Italy for a period
of 3 years from January 1, 2008, to December 31, 2010. Study start time could
differ among the centers, but all consecutive transplants were enrolled.
Second and third allo-HSCTs were analyzed as a separate category when
appropriate.
Data collection for each case was interrupted at 12 months after trans-
plantation, and thus the study end date was December 31, 2011. Data were
entered into electronic case report forms, and all reported results are
derived from the database frozen at June 30, 2012. The results of this study
are reported in accordance with the STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) statement [16]. The study was
approved by the Ethical Committee of each participating center, and
informed consent was obtained from the patients.
Data Collection
Variables analyzed included patient characteristics, diagnosis and phase
of the underlying disease; previous autologous HSCT (auto-HSCT) or allo-
HSCT; proven, probable, or possible IFD documented within the 180 days
before transplantation; cytomegalovirus (CMV) serology of donor and
recipient; stem cell donor; stem cell source; pretransplantation condition-
ing regimen; the use of total body irradiation; the use of in vivo T cell
depletion with antithymocyte globulin (ATG) or alemtuzumab; and the
transplantation activity of the center (with the median number of patients
enrolled [n ¼ 48] used to stratify 15 centers with high transplantation ac-
tivity and 15 centers with low activity). Post-transplantation data included
primary and secondary antifungal prophylaxis during the engraftment
phase and, in the event of graft-versus-host disease (GVHD), grade II-IV
acute GVHD (aGVHD) and extensive chronic GVHD (cGVHD) diagnosed
and staged according to standard criteria [17], CMV reactivation, remissionand causes of death. Information pertaining to PP-IFDs included timing after
allo-HSCT, microbiological data, and site of infection.
Case Deﬁnitions
Cases of PP-IFD were deﬁned according to standard international criteria
[18]. The clinical and laboratory data reported to deﬁne cases of PP-IFD were
reviewed to determine the reliability of the diagnosis. Cases with IFD diag-
nosed before transplantation were analyzed as a separate category when
appropriate. Onset of PP-IFD was deﬁned as the day of the ﬁrst positive
radiologic exam, positive culture, or positive pathological test. PP-IFDs were
classiﬁed as early (occurring 40 days after allo-HSCT), late (occurring 41 to
100 days after allo-HSCT), or very late (occurring 101 to 365 days after allo-
HSCT), consistent with previous analyses [9,10]. The cutoff of 40 days for
early PP-IFDs was chosen to ensure that the model reﬂected the engraftment
period. The day 41 to day 100 interval for late PP-IFDs reﬂects the immediate
postengraftment period, the risk of developing aGVHD, and early immuno-
logic recovery. The cutoff of 101 to 365 days for very late PP-IFDs reﬂects the
late or post-aGVHDperiod, the cGVHDperiod, and late immunologic recovery.
Analyses
The 12-month cumulative incidence of PP-IFDs was calculated ac-
counting for the competing risks of infection-free death, retransplantation,
and relapse of the underlying disease. The cumulative incidence of PP-IFDs
was calculated for any type and status of the underlying disease; any type of
stem cell donor, stem cell source, and pretransplant conditioning; history of
IFD before transplantation; type of primary antifungal prophylaxis; aGVHD
and cGVHD; and CMV infection/reactivation. Cumulative incidence was
assessed using the cmprsk package in R version 2.15 (R Project for Statistical
Computing, Vienna, Austria). The associations among early, late and very
late PP-IFDs and the foregoing risk factors were evaluated by landmark
analysis. All factors were evaluated in multivariate models to control for
potential confounders. Crude mortality rates at 100 days after PP-IFD and at
12 months post-transplantation were calculated. Death was attributed to a
PP-IFD in patients who failed to respond to therapy (ie, who had stable
disease or disease progression) and in patients who demonstrated a partial
response to therapy who died as the result of an acute event involving any of
the sites of infection and in the absence of any other causes considered to
have primarily contributed to death.
Survival analyses were performed on the basis of the foregoing vari-
ables. The probability of 1-year survival from allo-HSCT was calculated using
the Kaplan-Meier estimate, and the log-rank test was applied for univariate
analyses. A 2-sided P value <.05 was considered to indicate statistical sig-
niﬁcance. Multivariate analyses were performed with the Cox proportional
hazards regression model. The variables PP-IFD, aGVHD, cGVHD, and CMV
infection/reactivation in the model were considered time-dependent
covariates, with their effect evaluated only in the period after their onset.
All signiﬁcant variables in univariate analysis were included in multivariate
analysis; ﬁnal models were also evaluated with backward and stepwise
functions. In all, 95% conﬁdence intervals (CIs) are reported for the main
summary statistics, and all statistical comparisons were based on 2-tailed
tests. Statistical analyses were performed with SAS version 9.2 (SAS Insti-
tute, Cary, NC). All comparisons are 2-sided, with a nominal signiﬁcance
level of 5%.
RESULTS
Patient Characteristics
The 1858 allo-HSCTs analyzed in the study included 1771
ﬁrst allo-HSCTs, 85 second allo-HSCTs, and 2 third allo-HSCTs.
C. Girmenia et al. / Biol Blood Marrow Transplant 20 (2014) 872e880874Overall, 425 allo-HSCTs (22.9%) were preceded by an auto-
HSCT. The median number of transplants per center was
48.5 (range, 9 to 228). Demographic data and patient
characteristics at the time of allo-HSCT are summarized in
Table 1.
Antifungal Prophylaxis
During the engraftment period, 92 patients who had
experienced an IFD before transplantation (4.9%) receivedTable 1
Characteristics of Patients at Allo-HSCT (n ¼ 1858)
Characteristic Value
Age, yr, median (range) 43 (1-72)
Age 18 yr, n (%) 205 (11)
Male sex, n (%) 1072 (57.7)
Underlying disease, n (%)
Acute myelogenous leukemia 685 (36.9)
Acute lymphoblastic leukemia 325 (17.5)
Biphenotypic acute leukemia 7 (0.04)
Myelodysplastic syndromes 119 (6.4)
Chronic myeloprolipherative diseases 142 (7.6)
Non-Hodgkin lymphoma 192 (10.3)
Hodgkin lymphoma 90 (4.8)
Chronic lymphocytic leukemia 48 (2.6)
Aplastic anemia 68 (3.7)
Multiple myeloma and plasmacellular leukemia 122 (6.6)
Hemoglobinopaties 19 (1.0)
Solid tumors 15 (0.8)
Other diseases 26 (1.4)
Phase of underlying disease at allo-HSCT, n (%)
Malignancies in complete remission 977 (52.6)
Malignancies not in complete remission
remission/active*
768 (41.3)
Nonmalignant stable/ chronic diseases 113 (6.1)
Previous HSCT, n (%)
Auto-HSCT alone 418 (22.5)
Allo-HSCT (in 7 cases preceded by auto-HSCT) 87 (4.7)
Donor type, n (%)
HLA-matched related 849 (45.7)
HLA-mismatched relatedy 110 (5.9)
Unrelated volunteer 720 (38.7)
Unrelated cord blood 179 (9.6)
Stem cell source, n (%)
Bone marrow 581 (31.3)
Peripheral blood 1098 (59.1)
Cord blood 179 (9.6)
Pretransplantation conditioning, n (%)
Myeloablative 1179 (63.4)
Reduced-intensity 368 (19.8)
Nonmyeloablative 679 (36.5)
CMV serostatus (n ¼ 1803), n (%)
Recipient negative/donor negative 188 (10.4)
Recipient negative/donor positive 137 (7.6)
Recipient positive/donor positive 969 (53.7)
Recipient positive/donor negative 509 (28.2)
IFD in the 180 d before allo-HSCT, n (%) 93 (5.0)
Proven/probable IA 51 (54.8)
Proven candidosis 5 (5.4)
Proven/probable mucormycosis 3 (3.2)
Other proven/probable IFD 2 (2.1)
Possible IFD 32 (34.4)
Phase of previous IFD at allo-HSCT, n (%)
Infection in complete remission 44 (47.3)
Infection not in complete remission 49 (52.7)
Patients enrolled in the centers with the greatest
HSCT activity, n (%)
1381 (74.3)
Patients enrolled in the centers with the least
HSCT activity, n (%)
477 (25.7)
* Among 1017 patients with acute leukemia, 231 (26.7%) were not in CR
at the time of allo-HSCT.
y The 110 transplants from HLA-mismatched related donors included 72
haploidentical transplants.secondary antifungal prophylaxis, 1401 patients (75.4%)
received primary antifungal prophylaxis with ﬂuconazole
only, 263 (14.1%) received primary antifungal prophylaxis
with a mold-active drug, and 102 (5.5%) received no anti-
fungal prophylaxis. Among the 641 patientswho experienced
grade II-IV aGVHD and/or extensive cGVHD and did not
receive antifungal therapy owing to a previous IFD, only 133
(20.7%) receivedmold-active primary antifungal prophylaxis.
Considering that mold-active primary antifungal prophylaxis
in patientswith GVHDwas given in aminority of patients and
consisted of various drugs (liposomal amphotericin B, vor-
iconazole, itraconazole, posaconazole, and caspofungin)
administered alone or sequentiallywith heterogeneous start-
and-stop timing after transplantation and frequently with
intermittent administration, the variable “primary antifungal
prophylaxis” administered after engraftment in patients with
GVHD was not included in our risk analyses. In contrast,
primary antifungal prophylaxis administered during the
engraftment period was included in the variables considered
for the PP-IFD risk analysis.Incidence of PP-IFDs
Overall, in 164 of 1858 transplants (8.8%), a new PP-IFD or
reactivation of a previous IFD was documented before the
presence of any competing risk. IA was the most common
infection (133 cases; 81.1%), followed by invasive candidiasis
(18 cases, 11$0%), zygomycosis (6 cases, 3.7%), fusariosis
(3 cases, 1.8%), and infections by other fungi (Scedosporium
sp, Scopulariopsis sp, Cryptococcus neoformans, and Geo-
trichum capitatum, 1 case each).
The cumulative incidence of PP-IFDs was 5.1% at 40 days,
6.7% at 100 days, and 8.8% at 12 months from trans-
plantation (Figure 1). One competing risk was present in
769 cases (41.4%). The rate of PP-IFDs at the transplantationFigure 1. Cumulative incidence curve for IFDs among allo-HSCT recipients in
the GITMO epidemiologic survey.
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cumulative incidence of PP-IFD was 9.9% in the 15 centers
with the highest transplantation activity and 5.7% in the 15
centers with the lowest activity (P ¼ .004). The cumulative
incidence of PP-IFDs according to demographics, underlying
disease, and transplantation variables is presented in
Table 2.
Risk Factors for PP-IFD in the Early, Late, and Very Late
Phases after Allo-HSCT
The 164 cases of PP-IFD included 94 (57.3%) early, 39
(23.8%) late, and 31 (18.9%) very late cases. The early phase
had the highest rate of IFD irrespective of fungal pathogen
(Figure 3). In a landmark analysis, the cumulative incidence
of PP-IFDs was 5,1% in the early phase, 1.9% in the late phase,
and 2.9% in the very late phase. Risk factors for PP-IFD during
each phase after allo-HSCT are shown in Table 3.
On multivariate analysis, variables associated with early
PP-IFDs were receipt of a transplant from an unrelated
volunteer donor (UD) or cord blood (CB), active acute leu-
kemia at the time of transplantation, and an IFD before
transplantation. Late PP-IFDs were predicted by receipt of a
UD or CB transplant and grade II-IV aGVHD; very late
PP-IFDs, by grade II-IV aGVHD and extensive cGVHD. The
risk of early PP-IFD was greater (P ¼ .06) in centers with
higher transplantation activity compared with centers with
lower activity. Table 4 presents the cumulative incidence
estimates of PP-IFDs according to the variables identiﬁed as
independent risk factors during the various phases after
allo-HSCT.
Risk of PP-IFD in Patients with aGVHD or cGVHD
After excluding 20 patients who developed a PP-IFD
before the occurrence of GVHD, 641 patients who experi-
enced grade II-IV aGVHD and/or extensive cGVHD were
included in this analysis. A PP-IFD was documented in 28 of
388 patients (7.2%) with aGVHD not followed by cGVHD, in
25 of 129 patients (19.4%) with aGVHD followed by cGVHD,
and in 4 of 124 patients (3.2%) with cGVHD not preceded by
aGVHD (ie, “de novo” cGVHD). The median interval from the
onset of GVHD to detection of IFD was 38 days for patients
with aGVHD not followed by cGVHD, 80 days for patientsFigure 2. Distribution of total allo-HSCTs performed and the nuwith aGVHD followed by cGVHD, and 25.5 days for patients
with cGVHD not preceded by aGVHD (Figure 4).
The cumulative incidence of PP-IFD, starting from GVHD
onset, is shown in Figure 5 according to GVHD group and
donor type. In patients with aGVHD not followed by cGVHD,
the cumulative incidence of PP-IFD was 2.3% in recipients of
allo-HSCT from a matched related donor (MRD) and 10% in
recipients of allo-HSCT from an alternative donor (mis-
matched related donor [MMRD], UD, or CB) (P ¼ .0039). In
allo-HSCT recipients with aGVHD followed by cGVHD, the
cumulative incidence of PP-IFD was 10% in recipients of an
MRD graft and 25.3% in recipients of a graft from an alter-
native donor (P ¼ .06). In patients with de novo cGVHD, the
cumulative incidence of PP-IFD was 3% for the former group
3.5% for latter (P ¼ .90). The cumulative incidence of PP-IFDs
at 6 months after onset of GVHD was 7.1% in 334 patients
with a grade II aGVHD and 12.3% in 178 patients with grade
III-IV aGVHD (P ¼ .049).
Survival
The mortality rate at 100 days from the diagnosis of
PP-IFD was 46.3% (76 of 164 patients). In patients with IA,
invasive candidiasis, and non-Aspergillusenon-Candida in-
fections, it accounted for 48.5%, 39%, and 75%, respectively.
Among the 76 patients who died within 100 days from the
diagnosis of a PP-IFD, the infection was considered the pri-
mary cause of death in 34 (44.7%), with an attributable
mortality rate of 20.7%. The probability of survival to
6 months after diagnosis of PP-IFD was roughly 55% in pa-
tients in the early, late and very late phases after receipt of
allo-HSCT (Figure 6).
The overall survival of the entire population at 1 year after
allo-HSCT was 64.4% (95% CI, 62.2% to 66.6%). Multivariate
analysis identiﬁed older age, active acute leukemia at
transplantation, IFD in the 180 days before transplantation,
receipt of a CB transplant, receipt of a UD transplant, aGVHD,
and PP-IFD (hazard ratio [HR], 2.90; 95% CI, 2.32 to 3.62;
P < .0001) as independent survival factors (Table 5).
DISCUSSION
Few large, prospective surveillance studies on IFDs in allo-
HSCT recipients have been published to date [12,13]. A studymber and rate of IFDs in the 30 transplantation centers.
Table 2
Cumulative Incidence of IFD at 1 Year According to Demographic, Underly-
ing Disease, and Transplantation Variables
Variable Estimated
Cumulative
Incidence, %
95% CI P Value
Sex
Male 8.58 7.00-10.36 .66
Female 9.16 7.27-11.31
Underlying disease
Acute leukemia 8.95 7.29-10.80 .82
Other 8.68 6.90-10.71
Phase of underlying disease at allo-HSCT
CR 7.88 7.42-9.18 .02
No CR/chronic 10.37 8.47-12.49
Previous HSCT
No 9.02 7.57-10.62 .44
Yes, autologous alone 7.66 5.36-10.47
Yes, allogeneic 11.49 5.86-19.22
IFD in the 180 d before allo-HSCT
No 8.27 7.05-9.62 .0001
Yes 19.35 12.03-27.98
CMV serostatus
Donor positive,
recipient positive
7.33 5.80-9.08 .001
Donor positive,
recipient negative
7.30 3.72-12.47
Donor negative,
recipient positive
12.97 10.22-16.05
Donor negative,
recipient negative
5.32 2.72-9.19
Stem cell source
Bone marrow 9.12 6.96-11.64 <.0001
Peripheral blood 7.29 5.85-8.92
Cord blood 17.32 12.17-23.23
Donor type
HLA-matched related 4.60 3.34-6.17 <.0001
HLA-mismatched related 8.18 4.00-14.28
Unrelated volunteer 11.77 9.55-14.25
Unrelated cord blood 17.32 12.17-23.23
Conditioning regimen
Myeloablative 8.23 6.75-9.89 .24
Nonmyeloablative/
reduced-intensity
9.87 7.77-12.25
In vivo T cell depletion
No 5.32 3.93-7.00 <.0001
Yes 11.64 9.77-13.68
Total body irradiation
No 7.86 6.48-9.41 .03
Yes 11.07 8.64-13.84
Mold-active primary antifungal prophylaxis during engraftment
Yes 4.58 4.14-5.48 .02
No 8.95 7.90-10.15
Center HSCT activity
Highest 9.92 8.41-11.57 .004
Lowest 5.66 3.83-7.99
Figure 3. Timing of IFD. Early IFD refers to infection diagnosed on days 0-40
after allo-HSCT; late IFD, to infection diagnosed on days 41-100; and very late
IFD, to infection diagnosed after day 100.
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Associated Infections Surveillance Network (TRANSNET)
evaluated the incidence and burden of IFDs in 6666 alloge-
neic HSCTs performed between March 2001 and March 2006
in 23 transplantation centers (representing approximately
20% of HSCT recipients in the United States during the study
period) with the aim of estimating the cumulative incidence
of PP-IFDs and collecting clinical, diagnostic, and outcome
information for each reported infection [12]. A study by the
Prospective Antifungal Therapy (PATH) Alliance registry
collected data and monitored trends in epidemiologic char-
acteristics, diagnosis, treatment, and outcomes of 234 allo-
HSCT recipients with PP-IFD observed in 23 centers in the
United States and Canada between July 2004 and September
2007 [13].The present GITMO survey, which includes approximately
40% of allo-HSCTs performed in Italy during the years 2008 to
2010, was a prospective study designed to critically assess
not only the incidence, but also the risk factors for and
prognostic role of PP-IFDs at 1 year from allo-HSCT. A valu-
able characteristic of this study is the availability of complete
denominator data collected prospectively for consecutive
allo-HSCT recipients at each center.
The overall 12-month cumulative incidence of PP-IFDs
was 8.8%. Of these PP-IFDs, 81% were caused by IA and 11%
were caused by Candida species, with other infections rela-
tively uncommon. The incidence of PP-IFDs by allo-HSCT
graft source was 4.6% for MRD, 8.2% for MMRD, 11.8% for
UD, and 17.3% for CB. These results are comparable in some
respects to those reported in the TRANSNET survey, with
12-month cumulative incidences of 5.8% for MRD, 8.1% for
MMRD, and 7.7% for UD (with speciﬁc data for the few CB
transplants not reported) [12]. The incidence of PP-IFDs
among centers ranged from 0% to 23%, with the highest in-
cidences in the larger centers. A potential center effect may
represent a limit of our survey and of anymulticenter trial. To
evaluate the potential role of the different clinical care habits,
we stratiﬁed the centers according to transplantation activ-
ity, which may reﬂect the different types of transplants
and care capabilities. Multivariate analysis did not identify
transplantation activity as an independent risk factor,
although it was borderline signiﬁcant in the early phase after
allo-HSCT. The site-speciﬁc variation in the incidence of
PP-IFDs may reﬂect differences in patient populations,
transplantation programs, and diagnostic accuracy, particu-
larly for mold infections.
The timing of PP-IFDs in our study was rather unex-
pected: indeed, early infections represented 57.3% of all in-
fections documented during the ﬁrst year after allo-HSCT.
This result contrasts with previous studies in which the vast
majority of cases were documented after the engraftment
period [8,12]. Several factors may explain the high incidence
of PP-IFDs during the early transplantation phase in our se-
ries. Transplant with a UD or CB graft, active acute leukemia
at the time of transplantation, and an IFD before trans-
plantation were found to be independent factors for the
development of an early PP-IFD. One or more of these con-
ditions were present in more than one-half of the patients in
our study, in line with the increasing use of transplants from
alternative donors and a trend toward less-restrictive eligi-
bility criteria worldwide. The high risk for early IFDs in pa-
tients who receive a transplant from an alternative donor,
particularly CB, or in those with a history of infection before
Table 3
Risk Factors for IFD in 1858 Allo-HSCTs during the Early (Days 1-40), Late (Days 41-100) and Very Late (Days 101-365) Phases
Variable Early IFD (n ¼ 94) Late IFD (n ¼ 31) Very Late IFD (n ¼ 39)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age 1.0 (0.99-1.01) .81 0.97 (0.95-0.99) .02 0.99 (0.97-1.01) .57
Sex, female versus male 1.06 (0.70-1.59) .8 1.88 (0.92-3.83) .08 0.70 (0.36-1.35) .29
Underlying disease, acute leukemia versus
other
1.18 (0.78-1.77) .43 0.59 (0.29-1.2) .15 1.18 (0.63-2.24) .6
Phase of any underlying disease at allo-HSCT,
CR versus no CR
0.51 (0.34-0.78) .0017 0.76 (0.38-1.53) .44 1.01 (0.53-1.91) .98
Phase of the underlying disease at allo-HSCT
Acute leukemia in CR versus no CR 0.27 (0.16-0.46) <.0001 0.29 (0.17-0.49) <.0001 1.23 (0.27-5.56) .78 1.55 (0.37-6.53) .55
Other in CR versus acute leukemia no CR 0.30 (0.13-0.68) .004 0.39 (0.17-0.91) .03 1.96 (0.36-10.68) .44 0.64 (0.09-4.52) .65
Other no CR versus acute leukemia no CR 0.38 (0.23-0.63) .0002 0.45 (0.27-0.77) .003 2.04 (0.46-8.97) .35 1.44 (0.33-6.29) .63
Previous allo-HSCT, no versus yes 0.51 (0.25-1.06) .73 1.34 (0.18-9.83) .77 1.62 (0.23-11.6) .63
IFD in the 180 d before allo-HSCT, no versus
yes
0.26 (0.15-0.45) <.0001 0.27 (0.15-0.48) <.0001 0.39 (0.12-1.27) .12 Not converged
CMV serostatus
Donorþ/recipient versus donorþ/
recipientþ
1.31 (0.58-2.93) .51 1.30 (038-4.44) .68 Not converged
Donor/recipientþ versus donorþ/
recipientþ
1.98 (1.26-3.09) .003 1.25 (0.57-2.75) .58
Donor/recipient versus donorþ/
recipentþ
0.67 (0.27-1.69) .4 0.31 (0.04-2.36) .26
Stem cell source
Peripheral blood versus bone marrow 1.13 (0.69-1.86) .6 0.62 (0.29-1.34) .23 0.52 (0.27-1.01) .053
Cord blood versus bone marrow 3.23 (1.81-5.77) <.0001 1.67 (0.59-4.71) .34 0.94 (0.32-2.78) .91
Donor type
Mismatched related versus matched related 2.37 (0.94-5.92) .07 1.90 (0.75-4.81) .18 1.79 (0.21-15.1) .59 1.41 (0.16-12.14) .75 1.31 (0.30-5.73) .72
Unrelated volunteer versus matched related 2.76 (1.64-4.66) .0002 2.86 (1.68-4.84) .0001 5.05 (1.89-13.5) .001 3.73 (1.38-10.02) .009 1.80 (0.90-3.59) .09
Unrelated cord blood versus matched
related
5.45 (2.98-9.95) <.0001 4.60 (2.43-8.69) <.0001 6.05 (1.75-20.9) .004 4.64 (1.32-16.31) .017 1.83 (0.60-5.54) .29
Myeloablative conditioning, yes versus no 0.89 (0.59-1.34) .56 0.77 (0.38-1.56) .47 0.69 (0.37-1.3) .26
T cell depletion in conditioning, yes versus no 2.53 (1.58-4.04) .0001 1.8 (0.85-3.83) .12 2.26 (1.13-4.53) .02
Total body irradiation in conditioning, yes
versus no
1.51 (1.0-2.29) .05 1.54 (0.75-3.17) .24 1.18 (0.61-2.29) .63
Mold-active primary antifungal prophylaxis
during engraftment, yes versus no
0.46 (0.20-1.06) .06 0.69 (0.21-2.28) .54 0.53 (0.16-1.71) .29
Grade II-IV aGVHD 0.83 (0.25-2.74) .76 6.81 (3.14-14.8) <.0001 5.93 (2.71-12.98) <.0001 5.06 (2.60-9.85) <.0001 3.80 (1.90-7.59) .0002
Extensive cGVHD NA NA NA NA 5.99 (3.10-11.57) <.0001 3.98 (2.02-7.82) <.0001
CMV reactivation/infection 1.07 (0.33-3.54) .91 1.86 (0.92-3.79) .09 1.85 (0.98-3.50) .06
Center HSCT activity, highest versus lowest 2.39 (1.31-4.39) .005 1.85 (0.98-3.48) .06 1.88 (0.72-4.91) .19 1.08 (0.53-2.20) .84
NA indicates not applicable.
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Table 4
Cumulative Incidence of IFD According to the Variables Identiﬁed as Independent Risk Factors during the Early, Late, and Very Late Phases after Allo-HSCT
Variable Early IFD Late IFD Very Late IFD
Estimate, % 95% CI Estimate, % 95% CI Estimate, % 95% CI
Underlying disease and disease phase at allo-HSCT
Acute leukemia in CR 3.43 3.43-3.44 NS NS NS NS
Acute leukemia not in CR 12.12 12.03-12.21
Other disease in CR 3.78 3.74-3.82
Other disease not in CR 4.88 4.86-4.89
Previous IFD in the 180 d before allo-HSCT
No 4.48 4.47-4.48 NS NS NS NS
Yes 16.13 15.84-16.42
Donor type
Matched related 2.47 2.46-2.48 0.633 0.631-0.634 NS NS
Mismatched related 5.45 5.36-5.54 1.14 1.11-1.16
Unrelated volunteer 6.37 6.35-6.39 3.17 3.16-3.18
Unrelated cord blood 11.86 11.75-11.98 3.82 3.76-3.87
aGVHD grade
0-I NS NS 0.793 0.791-0.794 1.348 1.346-1.351
II-IV 4.36 4.34-4.37 6.52 6.49-6.55
cGVHD
None or limited NA NA NA NA 1.704 1.701-1.707
Extensive 8.06 8.0-8.12
NS indicates not signiﬁcant; NA, not applicable.
C. Girmenia et al. / Biol Blood Marrow Transplant 20 (2014) 872e880878transplantation is well known [5-7,10,19]; however, the high
rate of early PP-IFDs in patients with active acute leukemia at
the time of transplantation is an original ﬁnding. The severe
immunologic impairment associated with active disease,
multiple intensive chemotherapy treatments, and late
engraftment frequently seen in these patients may justify the
high early post-transplantation risk of PP-IFD [20-22].
GVHD represents a known risk factor for IFD, and mold-
active primary antifungal prophylaxis is recommended in
patients with GVHD while receiving initiation of immuno-
suppressive therapy [2,23,24]. Our study conﬁrms that
aGVHD and cGVHD are independent risk factors for the
development of late and very late PP-IFDs. The subanalysis of
patient populations with different types and severity of
GVHD and different donors revealed a signiﬁcantly different
risk proﬁle, however. The cumulative incidence of PP-IFDs
was high in patients with aGVHD developing after trans-
plantation from an alternative donor, and was even higher
when aGVHD was followed by cGVHD regardless of donor
type, up to 25% in recipients of an alternative donor graft. Of
interest, the cumulative incidence of PP-IFDs was relativelyFigure 4. Distribution of time to IFDlow (<4%) in patients with de novo cGVHD regardless of
donor type. As expected, the risk for PP-IFD was signiﬁcantly
higher in patients with grade III-IV aGVHD compared with
those with grade II aGVHD [2].
In this study, we were not able to evaluate the impact of
mold-active primary antifungal prophylaxis on the epide-
miology of post-transplantation PP-IFDs either during the
engraftment period or in the event of GVHD, likely related to
the wide variability in prophylaxis according to clinical
indication, type of antifungal drug, and timing and duration
of administration. The real life data from our study demon-
strate the difﬁculty of applying the guidelines for antifungal
prophylaxis in the various clinical settings of allo-HSCT, and
suggest the need for risk- and time-adapted indications
[14,24].
Reported mortality rates in allo-HSCT recipients with IFD
have been as high as 80% [1,13,25]; however, more recent
data seem to show improving outcomes, particularly for IA,
possibly related to the extensive use of voriconazole
[8,15,26]. In the PATH Alliance study, the overall mortality
rate at 12 weeks after documented IA was 35.5% [13],stratiﬁed by type of GVHD.
Figure 5. Cumulative incidence of IFD from GVHD onset by type of GVHD (A)
and by type of donor (B).
Figure 6. Probability of 6-month survival after diagnosis of early PP-IFD, late
PP-IFD, and very late PP-IFD.
C. Girmenia et al. / Biol Blood Marrow Transplant 20 (2014) 872e880 879compared with the 48.5% rate in our study. Of interest,
mortality attributed to PP-IFD was 20.7%, conﬁrming the
improvement in therapeutic approaches to these infections
with favorable impacts on short-term outcome.
Whereas in previous studies, outcomes of IFDs were
usually evaluated at 3 months after transplantation, weTable 5
Probability of Overall Survival at 1 Year from Allo-HSCT
Variable Univar
HR (95
Male versus female 0.99 (0
Age (increased by 10) 1.12 (1
Underlying disease, acute leukemia versus other 1.09 (0
Phase of any underlying disease at allo-HSCT, CR versus no CR 0.56 (0
Phase of the underlying disease at allo-HSCT
Acute leukemia in CR versus acute leukemia no CR 0.29 (0
Other in CR versus acute leukemia no CR 0.31 (0
Other no CR versus acute leukemia no CR 0.39 (0
Previous allo-HSCT, no versus yes 0.59 (0
Previous IFD in the 180 d before allo-HSCT, no versus yes 0.49 (0
CMV serostatus
Donorþ/recipient versus donorþ/recipientþ 0.99 (0
Donor/recipientþ versus donorþ/recipientþ 1.20 (1
Donor/recipient versus donorþ/recipientþ 0.85 (0
Stem cell source
Peripheral blood versus bone marrow 1.11 (0
Cord blood versus bone marrow 1.77 (1
Donor type
Mismatched related versus matched related 2.04 (1
Unrelated volunteer versus matched related 1.40 (1
Unrelated cord blood versus matched related 2.02 (1
Myeloablative conditioning, yes versus no 0.87 (0
T cell depletion in conditioning, yes versus no 1.25 (1
Total body irradiation in conditioning, yes versus no 0.98 (0
Center HSCT activity, highest versus lowest 1.08 (0
Grade II-IV aGVHD 1.58 (1
Extensive cGVHD 1.69 (1
CMV reactivation/infection 1.46 (1
PP-IFD after allo-HSCT, yes versus no 3.89 (3chose to evaluate outcomes at 1 year. In our study, in addi-
tion to the well-known factors predicting poor outcome,
including older age, active acute leukemia at transplantation,
IFD before transplantation, alternative donor graft, and
aGVHD, PP-IFDs represent an independent prognostic factor
for survival. This ﬁnding suggests that although PP-IFDs may
be cured or controlled in most cases, they are of poor prog-
nostic signiﬁcance, likely because of the underlying condi-
tion that favored the development of the infection, and also
because of the possible interference of IFD with the man-
agement of other post-transplantation complications, such
as GVHD, viral infection, and hematologic relapse.iate Analysis Multivariate Analysis
% CI) P Value HR (95% CI) P Value
.85-1.16) .9
.06-1.17) <.0001 1.14 (1.10-1.19) <.0001
.93-1.27) .28
.48-0.66) <.0001
.23-0.35) <.0001 0.36 (0.29-0.45) <.0001
.23-0.42) <.0001 0.41 (0.30-0.56) <.0001
.32-0.48) <.0001 0.49 (0.40-0.61) <.0001
.43-0.80) .0006
.37-0.65) <.0001 0.57 (0.43-0.76) 0.0001
.73-1.35) .94
.01-1.43) .04
.64-1.12) .27
.93-1.32) .24
.37-2.29) <.0001
.52-2.74) <.0001 1.81 (1.34-2.44) <.0001
.18-1.66) .0001 1.34 (1.13-1.60) <.0001
.58-2.59) <.0001 1.81 (1.40-2.35) <.0001
.75-1.02) .09
.07-1.46) .004
.83-1.16) .79
.91-1.29) .39
.34-1.86) <.0001 1.46 (1.23-1.72) <.0001
.31-2.19) <.0001
.24-1.72) <.0001
.14-4.79) <.0001 2.90 (2.32-3.62) <.0001
C. Girmenia et al. / Biol Blood Marrow Transplant 20 (2014) 872e880880In conclusion, our study has identiﬁed important risk
factors for PP-IFD during the preengraftment and post-
engraftment phases in a real life allo-HSCT scenario. The
demonstration of an independent impact of these compli-
cations on transplantation outcomes suggests the need for
changes in supportive care strategies to decrease the burden
of IFD in allo-HSCT recipients. Of relevance, our experience
shows an absence of consensus in the practice of antifungal
prophylaxis in the allo-HSCT community, likely related to the
lack of speciﬁc epidemiologic information. Our present
ﬁndings may be useful in identifying the subpopulations of
allograft recipients who might beneﬁt from targeted pre-
vention strategies.
ACKNOWLEDGMENTS
The authors thank Roberto Ricci for his valuable assis-
tance with data management.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Financial disclosure: The authors have nothing to disclose.
REFERENCES
1. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould
infections in hematopoietic stem cell transplant recipients. Clin Infect
Dis. 2002;34:909-917.
2. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic
stem cell transplant recipients: changes in epidemiology and risk fac-
tors. Blood. 2002;100:4358-4366.
3. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive
fungal infections in recipients of allogeneic hematopoietic stem cell
transplants after nonmyeloablative conditioning. Blood. 2003;102:
827-833.
4. Saavedra S, Sanz GF, Jarque I, et al. Early infections in adult patients
undergoing unrelated donor cord blood transplantation. Bone Marrow
Transplant. 2002;30:937-943.
5. Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood
transplantations: spectrum of early and late post-transplant infections
in adult and pediatric patients, 1996-2005. Medicine (Baltimore). 2007;
86:324-333.
6. Miyakoshi S, Kusumi E, Matsumura T, et al. Invasive fungal infection
following reduced-intensity cord blood transplantation for adult pa-
tients with hematologic diseases. Biol Blood Marrow Transplant. 2007;
13:771-777.
7. Parody R, Martino R, Rovira M, et al. Severe infections after unrelated
donor allogeneic hematopoietic stem cell transplantation in adults:
comparison of cord blood transplantation with peripheral blood and
bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12:
734-748.
8. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following
hematopoietic cell transplantation: outcomes and prognostic factors
associated with mortality. Clin Infect Dis. 2007;44:531-540.
9. Garcia-Vidal C, Upton A, Kirby KA, Marr A. Epidemiology of invasive
mold infections in allogeneic stem cell transplant recipients: biological
risk factors for infection according to time after transplantation. Clin
Infect Dis. 2008;47:1041-1050.
10. Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive asper-
gillosis and related mortality in recipients of allogeneic SCT fromalternative donors: an analysis of 306 patients. Bone Marrow Trans-
plant. 2009;44:361-367.
11. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of
hematopoietic stem cell transplants: results of the SEIFEM B-2004
study (Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie
Maligne). Clin Infect Dis. 2007;45:1161-1170.
12. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for
invasive fungal infections in hematopoietic stem cell transplant re-
cipients, 2001-2006: overview of the Transplant-Associated Infection
Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:
1091-1100.
13. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of
invasive fungal infection in adult hematopoietic stem cell transplant
recipients: analysis of the Multicenter Prospective Antifungal Therapy
(PATH) Alliance registry. Clin Infect Dis. 2009;48:265-273.
14. Girmenia C, Barosi G, Aversa F, et al. Prophylaxis and treatment of
invasive fungal diseases in allogeneic stem cell transplantation: results
of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo
(GITMO). Clin Infect Dis. 2009;49:1226-1236.
15. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic
review of the literature. Clin Infect Dis. 2001;32:358-366.
16. von Elm E, Altman DG, Egger M, et al, STROBE Initiative. The
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) statement: guidelines for reporting observational studies.
J Clin Epidemiol. 2008;61:344-349.
17. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host
syndrome in man: a long-term clinicopathologic study of 20 Seattle
patients. Am J Med. 1980;69:204-217.
18. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised deﬁnitions of invasive
fungal disease from the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and
the National Institute of Allergy and Infectious Diseases Mycoses
Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:
1813-1821.
19. Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the
pretransplantation conditioning regimen in patients with prior inva-
sive aspergillosis undergoing allogeneic hematopoietic stem cell
transplantation: a retrospective survey of the Infectious Diseases
Working Party of the European Group for Blood and Marrow Trans-
plantation. Blood. 2006;108:2928-2936.
20. Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after
unrelated donor stem cell transplantation in primary refractory acute
myeloid leukaemia. Leukemia. 2011;25:808-813.
21. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation
for acute leukemia in relapse or primary induction failure. J Clin Oncol.
2010;28:3730-3738.
22. Todisco E, Ciceri F, Oldani E, et al. The CIBMTR score predicts survival of
AML patients undergoing allogeneic transplantation with active dis-
ease after amyeloablative or reduced intensity conditioning: a retro-
spective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo
(GITMO). Leukemia. 2013;27:2086-2091.
23. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood
Marrow Transplant. 1999;5:55-68.
24. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for
antifungal management in leukemia and hematopoietic stem cell
transplant recipients: summary of the ECIL 3-2009 update. Bone
Marrow Transplant. 2011;46:709-718.
25. Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death
due to invasive aspergillosis after hematopoietic stem cell trans-
plantation: a 1-year retrospective study of consecutive patients at
French transplantation centers. Clin Infect Dis. 2006;42:955-963.
26. Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality
in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;
50:1559-1567.
